Andrew Allen

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Verge Analytics, Inc. engages in the provision of biotechnology services. It develops drugs for neurodegenerative diseases using computational genomics. The company was founded by Alice Zhang and Jason Chen in 2015 and is headquartered in San Francisco, CA.

Revitope Oncology, Inc. develops a programmable antibody circuit pipeline in particular redirecting T cells to tumors. The company was founded by Andrew Allen and Mark Cobbold and is headquartered in Cambridge, MA.

Cell Design Labs, Inc. develops disruptive cell-based therapies for cancer and other devastating diseases. The company was founded by Brian G. Atwood and Fred E. Cohen in 2016 and is headquartered in Emeryville, CA.

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Peptone Ltd. offers state of the art solutions for protein biotechnology. The firm involves in protein biotechnology research with peer reviewed science, novel use of advanced machine learning and autonomous artificial intelligence. The company was founded by Kamil Tamiola and Matthew Michael Heberling in 2016 and is headquartered in London, the United Kingdom.